An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines
- 2 July 2020
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 61 (8), 1860-1868
- https://doi.org/10.1080/10428194.2020.1747064
Abstract
Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of lenalidomide and dexamethasone as frontline pre-transplant induction, with doses adjusted at start of each cycle based on creatinine clearance, as per the official dosing guidelines. After 4 cycles, PK studies showed that patients with moderate RI (30 <= CrCl < 60 mL/min) receiving 10 mg dosing may be under-dosed and those with severe RI (CrCl <30ml/min) appeared appropriately dosed initially, but sustained significant decreases in maximum serum concentration (Cmax) after repeated dosing, due to rapid clinical improvement and enhanced drug clearance. PK drug monitoring during cycle 1 may facilitate appropriate and timely dose adjustments. Adverse events rates did not vary based on severity of RI. No patient discontinued lenalidomide for toxicity. This supports the feasibility and safety of frontline lenalidomide in transplant-eligible patients with RI.Keywords
This publication has 18 references indexed in Scilit:
- Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agentsAnnals Of Oncology, 2014
- Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairmentAnnals of Hematology, 2010
- Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective studyEuropean Journal of Haematology, 2010
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionCancer, 2010
- Meeting the Unmet Needs in Anticoagulant TherapyEuropean Journal of Haematology, 2010
- Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairmentEuropean Journal of Haematology, 2010
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myelomaBlood Reviews, 1999
- Renal Failure in Multiple MyelomaArchives of Internal Medicine, 1998
- Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patientsEuropean Journal of Haematology, 1994